Skip to main content

Table 1 Characteristics of the included studies

From: The effect of tranexamic acid in patients with TBI: a systematic review and meta-analysis of randomized controlled trials

 TrailCountryTranexamic acid groupPlacebo group
NumberAge (years)MethodFollow-upNumberAge (years)Follow-up
1Chakroun-Walha 2019 [11]Tunisia9644.0 ± 20.0VTA was administered as soon as possible, with a first dose of 1 g in 100 ml of normal saline in 10 min and then with a maintenance dose of 1 g per 500 ml of normal saline for 8 h28 days8439 ± 1828 days
2CRASH-2 trial collaborators 2011 [10]India and Colombia12336.0 ± 14.0VTA was administered with the first dose of 1 g in 100 ml of normal saline in 10 min and then with a maintenance dose of 1 g per 1000 ml of normal saline for 8 h28 days12637 ± 1428 days
3CRASH-3 trial collaborators 2019 [5]UK461341.7 ± 19.0VTA was administered with the first dose of 1 g in 100 ml of normal saline over 10 min, followed by an intravenous infusion of 1 g over 8 h28 days451441.9 ± 19.028 days
4Fakharian 2018 [12]Iran7442.3 ± 18.3VTA was administered with the first dose of 1 g in 100 ml of normal saline in 10 min and then with a maintenance dose of 1 g per 1000 ml of normal saline for 8 h3 months7539.3 ± 18.13 months
5Roberts 2013 [4]UK1006034.6 ± 14.1VTA (loading dose of 1 g of VTA infused over 10 min, followed by an intravenous infusion of 1 g over 8 h)28 days10,06734.5 ± 14.428 days
6Yutthakasemsunt 2013 [13]Thailand12034.8 ± 16.0VTA (loading dose of 1 g over 30 min followed by a maintenance dose of 1.0 g infused over 8 h)24–32 h11834.1 ± 15.324–32 h